Ki H. Lee, MD

Ki H. Lee, MD

Pediatric Neurologist, Epileptologist

Neuroscience

Ki Hyeong Lee

Overview

Ki Hyeong Lee, MD, MS, is a board-certified neurologist and epileptologist with AdventHealth Medical Group and the Medical Director of AdventHealth for Children’s pediatric epilepsy center in Orlando. A leading provider of diagnostic and surgical techniques for addressing epilepsy and seizures, Dr. Lee completed three prestigious fellowships in clinical neurophysiology, epilepsy research and stroke at the Medical College of Georgia, Mayo Clinic Foundation in Minneapolis and Seoul National University Hospital in Korea, respectively. A noted researcher who regularly presents his work in published articles and international medical forums, he constantly seeks to advance the state of epilepsy patient care through medical breakthroughs and new technologies.

Articles

Intracranial EEG and laser interstitial thermal therapy in MRI-negative insular and/or cingulate epilepsy: case series

JOURNAL OF NEUROSURGERY

2021

Deep Learning Provides Exceptional Accuracy to ECoG-Based Functional Language Mapping for Epilepsy Surgery

FRONTIERS IN NEUROSCIENCE

2020

Altered integrity of corpus callosum in generalized epilepsy in relation to seizure lateralization after corpus callosotomy

NEUROSURGICAL FOCUS

2020

Anakinra usage in febrile infection related epilepsy syndrome: an international cohort

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY

2020

Epilepsy Surgery in Children versus Adults

JOURNAL OF KOREAN NEUROSURGICAL SOCIETY

2019

Usefulness of intraoperative insular electrocorticography in modified functional hemispherectomy

BMC NEUROLOGY

2017

Impact of intraoperative 3-T MRI with diffusion tensor imaging on hemispherectomy

JOURNAL OF NEUROSURGERY-PEDIATRICS

2017

The role of executive functioning in quality of life in pediatric intractable epilepsy

EPILEPSY & BEHAVIOR

2016

Identification of Focal Epileptogenic Networks in Generalized Epilepsy Using Brain Functional Connectivity Analysis of Bilateral Intracranial EEG Signals

BRAIN TOPOGRAPHY

2016

Electrocorticography-Based Real-Time Functional Mapping for Pediatric Epilepsy Surgery

JOURNAL OF PEDIATRIC EPILEPSY

2015

More Publication Information

Education & Training

Education

Seoul National University College of Medicine

Fellowship

Medical College of Georgia

Specialty

Pediatric Neurology

Board Certifications

American Board of Psychiatry and Neurology

Associated Clinical Trials

NCT04391569

A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of intravenous ganaxolone in status epilepticus

This study is currently enrolling.

The purpose of this research is to find out if ganaxolone can stop or decrease the seizure activity in participants who have SE and if ganaxolone is safe compared to placebo when given to participants who are on other anti-seiz ...

NCT05076838

An Open-Label, Single-Dose, Pharmacokinetics Study of VALTOCO with Open-Label Safety Period in Pediatric Subjects with Epilepsy

This study is currently enrolling.

This is a research study to evaluate the pharmacokinetics (PK), safety and tolerability after a single intranasal dose of VALTOCO (diazepam nasal spray), followed by a long-term safety period, where VALTOCO will be used “as nee ...

NCT04740476

SWALLOWTAIL Study – An Open-Label Extension Study for Patients with Dravet Syndrome who Previously Participated in Studies of STK-001

This study is currently enrolling.

The main purpose of this extension study is to look at how safe STK-001 is when given every 4 months over a year. The study will also look at how well a person can tolerate receiving multiple doses of the study drug.

NCT05128344

Amzell B.V. / A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of AMZ002, Compared to Vigabatrin, in the Treatment of Infantile Spasms

This study is currently enrolling.

The main purpose of this study is to learn how well AMZ002 works and how safe it is compared with a similar drug called vigabatrin. Vigabatrin is a drug that is currently approved for use by the US FDA and in other countries to ...

NCT05364021

A Phase 1b/2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Dose-Escalation Study to Investigate the Safety, Tolerability, pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies

This study is currently enrolling.

LP352 is being studied to see if it might reduce the number of seizures in patients with DEE. LP352 is thought to work by activating specific sites in the brain that are associated with seizure disorders.